Gossamer Bio Q3 net loss $40M, cash sufficient into H1 2026; PROSERA study ahead

Gossamer Bio, Inc.

2023-Q3 EPS reported -$1.03

Net loss $40.0M ($0.21/share) vs $59.4M loss in Q3 2022; R&D expenses $31.2M (down from $44.5M).
Cash, equivalents & marketable securities $328.9M; expected to fund operations into first half of 2026.
Phase 3 PROSERA site activations ahead of schedule; first patient dosing expected in Q4 2023.
Additional TORREY open-label extension data (seralutinib in PAH) expected in Q4 2023.
FRI sub-study of TORREY presented at ERS 2023; evidence of improved pulmonary blood vessel volume.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Gossamer Bio, Inc. reported third quarter ended September 30, 2023 results: net income $40.0 million, or $0.21 per share, EPS $0.21 per share.

Period: third quarter ended September 30, 2023
Net income: $40.0 million, or $0.21 per share
EPS: $0.21 per share
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2023, was $40.0 million, or $0.21 per share, compared to a net loss of $59.4 million, or $0.65 per share, for the same period in 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-23-000133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.